MRTX849 in Patients With Cancer Having a KRAS G12C Mutation



Status:Recruiting
Conditions:Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/26/2019
Start Date:January 15, 2019
End Date:April 2020
Contact:Mirati Therapeutics Study Locator Services
Email:miratistudylocator@emergingmed.com
Phone:1-844-893-5530

Use our guide to learn which trials are right for you!

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of
MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.

Evaluate the safety, tolerability, pharmacokinetics, metabolites, pharmacodynamics, and
clinical activity of MRTX849 in patients with advanced solid tumors with a KRAS G12C
mutation. MRTX849 is an orally-available small molecule inhibitor of KRAS G12C.

Inclusion Criteria:

- Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation

- Unresectable or metastatic disease

- Standard treatment is not available or patient declines

- Adequate organ function

Exclusion Criteria:

- Active brain metastases

- History of intestinal disease or major gastric surgery or inability to swallow oral
medications

- Other active cancer
We found this trial at
3
sites
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Orange, California 92868
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials